Table 3.
Patient Characteristics Associated with Recommended Osteoporosis Management
| Characteristics | Managed (N = 60) | Not managed (N = 114) | P value |
|---|---|---|---|
| Age at diagnosis (y) | 68.4 (8.1) | 71.2 (8.7) | 0.04 |
| Duration of cancer diagnosis (y) | 7.5 (4.6) | 6.6 (4.5) | 0.24 |
| Race | |||
| Non-Hispanic White | 36 (50.0%) | 36 (50.0%) | 0.0002 |
| Hispanic | 19 (30.6%) | 43 (69.4%) | |
| Other* | 4 (30.8%) | 9 (69.2%) | |
| Unknown | 1 (3.8%) | 26 (96.2%) | |
| BMI | 27.0 ± 4.3 | 27.9 ± 5.8 | 0.31 |
| Gleason | 7.0 ± 1.3 | 6.8 ± 1.2 | 0.63 |
| Last PSA | 74.6 ± 194.8 | 5.4 ± 18.2 | 0.0002 |
| Number of ADT shots | 10.1 ± 7.1 | 7.6 ± 6.5 | 0.02 |
| Concurrent medications | |||
| Corticosteroid | 16 (55.2%) | 13 (44.8%) | 0.01 |
| Thyroid hormone | 6 (35.3%) | 11 (64.7%) | 0.94 |
| Phenytoin | 0 (0%) | 2 (100%) | 0.30 |
| History of hip or vertebral fracture | 9 (47.4%) | 10 (52.6%) | 0.21 |
| Diabetes | 13 (46.4%) | 25 (53.6%) | 0.97 |
| Cigarette smoking | 9 (47.4%) | 19 (52.6%) | 0.78 |
| Alcohol | 14 (93.3%) | 1 (0.07%) | 0.61 |
| Bone metastases | 23 (71.9%) | 9 (28.1%) | <0.0001 |
Values are mean (SD) unless otherwise indicated.
*Other: African American, Native American, Asian American, or Pacific Islander